Global private equity firm Carlyle said on Wednesday it led a $312 million funding round for Japanese biotech company Spiber Inc, joining other global investors in betting on a growing number of late-stage Japanese startup firms.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in